Quick Facts

• Relief of Temporary Constipation: Utilized for the short-term management of infrequent bowel movements.
• Promotes Regularity: Supports the maintenance of predictable bowel function.
• Stool Passage: Assists in making the passing of stools easier.

---

What Agarol Treats: Main Uses and Benefits

Agarol is a product indicated for the temporary relief of constipation. It functions as a supportive agent in the management of infrequent or difficult bowel movements. The primary use of this formulation is to facilitate the stool passage process, which may help to normalize bowel function during periods of temporary irregularity.

In the context of digestive health, Agarol is intended to address the symptoms associated with occasional constipation. Its application is focused on aiding in relief from the discomforts associated with these episodes. The formulation is utilized to promote regularity and support the overall process of defecation.

This over-the-counter product is employed when a lubricant laxative is deemed appropriate for symptomatic relief of acute or short-lived constipation.

Who can and cannot use Agarol?

Official regulatory documents strictly define the patient populations eligible for Agarol (Sodium Picosulfate and Liquid Paraffin) use.

Absolute Contraindications The medicine is strictly forbidden for patients with acute gastrointestinal pathologies, including intestinal obstruction, bowel perforation, toxic megacolon, or acute inflammatory bowel diseases. It is also absolutely contraindicated in children under 3 years of age. Individuals with severe dehydration or known hypersensitivity to any component are also excluded from use.

Restricted and Conditional Use Use is reserved exclusively for temporary relief; prolonged or chronic use is not permitted. Due to the Liquid Paraffin component, patients with difficulty swallowing or conditions that increase the risk of aspiration should not use the product. Use in pregnant or breastfeeding individuals is not recommended unless specifically advised by a medical professional. For children between the ages of 3 and 12, use is restricted and generally requires professional advice. Caution is required for populations with co-existing renal impairment or heart disease.

Agarol Interactions with other medicines and products

The official interaction profile for Agarol (Sodium Picosulfate and Liquid Paraffin) is defined by both pharmacodynamic potentiation and pharmacokinetic interference, as documented in regulatory labeling.

---

Documented Interaction Patterns

Interactions Affecting Exposure and Absorption

Co-administration with orally administered medicinal products (e.g., oral contraceptives, oral anti-epileptics) may reduce the systemic exposure of the co-administered drug. This is due to the dual action of Liquid Paraffin creating a physical barrier to absorption and Sodium Picosulfate increasing gastrointestinal transit time. Therefore, administration must be separated by at least two hours from other oral medications.

Additionally, Liquid Paraffin interferes with the absorption of fat-soluble vitamins (A, D, E, K), which may reduce their systemic levels when supplements are taken concurrently.

Pharmacodynamic and Efficacy Interactions

Co-administration with diuretics (e.g., loop or thiazide diuretics) and corticosteroids may lead to pharmacodynamic reinforcement, increasing the risk of potassium loss (hypokalaemia). The regulatory label notes this risk is heightened in the elderly and individuals with pre-existing electrolyte disturbances.

Furthermore, the laxative effect of Sodium Picosulfate may be reduced by co-use with broad-spectrum oral antibiotics, as these may diminish the colonic bacteria necessary for the laxative’s activation. Official restrictions advise against combining Agarol with other laxatives due to the risk of an additive effect and electrolyte imbalance.

Pro-drug Activation and Enhanced Peristalsis

Agarol's action relies on a non-systemic dual mechanism. The stimulant component, Sodium Picosulfate, operates as an inactive pro-drug until it reaches the colon. Here, colonic bacterial sulfatase enzymes hydrolyze it to yield the active metabolite, BHPM (Bis-(p-hydroxy-phenyl)-pyridyl-2-methane). This metabolite stimulates the sensory nerve endings and epithelial cells within the colon. This direct contact stimulation increases the frequency and force of propulsive muscle contractions (peristalsis), influencing the downstream movement of luminal contents.

---

Dual Action on Fluid Transport and Lubrication

Complementing the motor action, the active metabolite BHPM modulates the colonic epithelium to inhibit the net reabsorption of water and electrolytes while promoting their secretion into the lumen, resulting in a net increase of fluid within the colon. Concurrently, Liquid Paraffin provides a mechanical, non-absorbable component. It creates an oil film that coats the fecal mass and mucosal wall, serving as an emollient to reduce frictional resistance. This synergy of motor enhancement, fluid regulation, and physical lubrication facilitates the movement of luminal contents.

How Agarol is Used: General Administration Guidelines

The principles for using Agarol (a combination product containing Sodium Picosulfate and Liquid Paraffin) involve instructions detailing the proper route, dosing, frequency, and administration context.

---

Administration Scope

The medicine is designed for oral administration as an emulsion or solution. The use pattern involves a single daily dose, most commonly administered in the evening to facilitate a bowel movement the following morning.

Category	Standard Instruction
Route of Administration	Oral administration only.
Dosing Schedule (Adults)	Typically 10 mL to 30 mL of the liquid, taken once daily.
Timing and Frequency	Once daily, preferably taken at bedtime (in the evening).
Course Duration	Strictly for short-term use, often limited to a maximum of seven consecutive days.

---

Procedural Instructions and Adjustments

Prior to measuring the dose, the container of oral emulsion must be shaken well to ensure the uniform distribution of its components. The measured dose may be mixed with water or other liquid for intake. One administration condition involves avoiding lying down immediately after swallowing the dose.

Dosing schedules are subject to adjustment based on age. For Older Adults, a lower starting dose may be appropriate. For Pediatric Patients (typically children aged 6 to 12 years), a reduced volume, such as 5 mL to 10 mL once daily, is described. Use in children under 6 years is generally restricted unless specifically advised by a healthcare professional.

The Research Landscape for Laxatives and Combination Therapy

Official regulatory documents and peer-reviewed literature indicate that the research base for Agarol, which combines Sodium Picosulfate and Liquid Paraffin, involves studies of both the individual components and, less frequently, the specific combination itself. This medicine was evaluated in research exploring how symptoms change over time in people experiencing constipation. Studies focusing on laxative treatments typically utilize Randomized Controlled Trials (RCTs) to assess functional outcomes, comparing an active agent to a placebo or another treatment. The findings from these trials contribute to the broader evidence landscape, describing how patients reported their experience during defined observation periods.

Evidence for this approach is often drawn from systematic reviews and analyses that monitored patient-reported outcomes related to functional imbalance. Research examines outcomes related to functional imbalance and physical discomfort that may accompany conditions characterized by fluctuating or episodic manifestations.

---

Evidence for Temporary and Chronic Constipation Management

Research has been examined for the use of these ingredients in patients experiencing conditions associated with acute or episodic manifestations of constipation. Studies were conducted during periods of increased symptom activity, focusing on episodes where symptoms become more noticeable. Researchers designed trials to monitor specific functional measures.

Design of Key Clinical Trials

The evidence quality varies across studies, particularly when looking at the specific dual-agent product. Sodium Picosulfate and Liquid Paraffin have each been evaluated in separate clinical trials. However, the specific combination formula has more often been evaluated in non-comparative research or in studies where a third component, such as Milk of Magnesia, was also present. A limitation of the research is that comparative evidence against a placebo is lacking when assessing the specific two-drug combination alone. The results apply only to the populations studied and the specific conditions under which the research was conducted.

---

Long-Term Studies and Duration of Follow-up

Research exploring the duration of effect and maintenance of function is relatively limited for this class of combination laxatives. Studies typically focused on short-term symptom changes, with most follow-up durations limited to acute periods of a few days or intermediate periods of up to four weeks. Long-term outcomes are not fully established, and the research literature contains limited information from studies with extended follow-up durations for this type of combination.

---

Key Limitations and Uncertainty in the Evidence

Evidence for the direct contribution of each component when assessed together is limited due to the structure of available studies. The research highlights what is known and what is still uncertain. Data for certain groups remain insufficient, and research is ongoing to explore temporary physiological imbalance in a wider range of settings.

Key Studies & References

1. Sodium Picosulfate: MedlinePlus Drug Information
2. Rome IV Criteria for Functional Gastrointestinal Disorders (Constipation Subtypes)

Common questions about Agarol (FAQ)

Q: Is it safe to take Agarol while I'm pregnant or breastfeeding?

Official product information indicates that use during pregnancy is generally not recommended, primarily because comprehensive studies in pregnant women are limited. For breastfeeding, the active component (Sodium Picosulfate metabolite) has been reported as undetectable in breast milk in some studies. However, the use of this medication during breastfeeding requires professional evaluation and guidance.

Q: Why does the package say to avoid lying down right after taking it?

Regulatory documents explain this warning is related to the Liquid Paraffin component of Agarol. Avoiding lying down immediately after taking the dose helps prevent the risk of accidental inhalation (aspiration) of the oil. If the oil enters the lungs, it can potentially cause a serious lung condition known as Lipoid Pneumonia.

Q: I am taking oral contraception. Will Agarol stop my birth control from working?

Official drug labels indicate that Agarol may potentially reduce the systemic exposure (the amount absorbed into the body) of other orally taken medications, which includes oral contraceptives. To help mitigate this potential interaction, regulatory labels recommend separating the administration of Agarol from any other oral medication by at least two hours.

Q: Can I take Agarol for chronic constipation?

According to official regulatory documents, Agarol is strictly indicated only for the short-term relief of acute and temporary constipation. The product is not intended or recommended for prolonged or chronic use.

Q: How long does it take for Agarol to work?

The stimulant component, Sodium Picosulfate, requires activation by bacteria in the colon before it begins working. Due to this natural process, the onset of the laxative effect generally occurs between 6 and 12 hours after the dose is taken. This expected time of effect aligns with the common guidance for administration in the evening (at bedtime).

Q: What is Lipoid Pneumonia, and how does Agarol cause it?

Lipoid Pneumonia is a serious potential adverse reaction noted in the product's safety information. It occurs if the Liquid Paraffin component of the emulsion is accidentally inhaled (aspirated) into the lungs. In the lungs, the oil can act as a foreign substance, leading to an inflammatory reaction.

Storage of Agarol

Agarol oral emulsion must be stored according to specific regulatory requirements to maintain its stability. The product should be kept at room temperature, typically specified as below 25°C (77°F).

It is strictly required to not refrigerate and not freeze this medicine. To protect the formulation, the bottle must be kept tightly closed and stored in its original container to shield it from light and excessive moisture.

As a mandatory safety precaution, the medicine must be stored out of the sight and reach of children and pets.

Disposal of Unused or Expired Agarol

Official disposal guidance recommends utilizing a drug take-back program or mail-back envelope for unused or expired medicine. Disposal via the household trash is permitted only if the product is first mixed with an undesirable substance (such as dirt) and sealed in a container, as the medicine must not be thrown away in wastewater or the toilet.